Evaluation of immune response following one dose of an AS03_A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

Figures & data

Table 1. Immune response in terms of HI antibodies against the vaccine homologous A/California/7/2009 strain at all evaluation time points (ATP cohort for immunogenicity)

Age group	N	Seroprotection rate	Seroconversion rate	Geometric Mean titer	Geometric Mean Fold Rise
		% (95% CI)	% (95% CI)	Value (95% CI)	Value (95% CI)
Pre-vaccination	50	4.0% (0.5–13.7)	–	6.6 (5.5–7.9)	–
Day 21	50	64.0% (49.2–77.1)	60.0% (45.2–73.6)	67.2 (46.1–98.0)	10.2 (6.9–14.9)
Month 6	49	42.9% (28.8–57.8)	38.8% (25.2–53.8)	27.6 (19.2–39.8)	4.2 (3.0–6.0)

N, number of subjects with available results; CI, confidence interval

Table 2. Immune response in terms of neutralizing antibodies against the A/Netherlands/602/09 strain [antigenically homologous to the vaccine strain] at all evaluation time points (ATP cohort for immunogenicity)

Time point		Vaccine Response Rates	Geometric Mean titers
	N	% (95% CI)	Value (95% CI)
Pre-vaccination	50	–	7.7 (5.8–10.1)
Day 21	50	40.0% (26.4–54.8)	29.3 (18.6–46.0)
Month 6	49	30.6% (18.3–45.4)	20.4 (14.4–28.7)

N, Number of subjects with available results; CI, Confidence interval

Figure 1. Percentage of subjects reporting solicited local adverse events during the 7-d post-vaccination follow-up period (Total vaccinated cohort).

Figure 2. Percentage of subjects reporting solicited general adverse events during the 7-d post-vaccination follow-up period (Total vaccinated cohort).